Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GYM329 on Disuse Muscle Atrophy in Healthy Volunteers
NCT04708847Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of emugrobart in Disuse muscle atrophy (DMA) (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Thigh muscle strength score at 28 days. Started Feb 2021; status: completed.
02
Drugs
emugrobart
03
Conditions
Disuse muscle atrophy (DMA)
Beyond the preview
Go deeper on NCT04708847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708847.